Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

During the COVID pandemic's height, for example, Pfizer was not only the co-developer of the widely distributed Comirnaty vaccine, it was also the entity behind the go-to drug therapy Paxlovid.

Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined steeply in 2023 due to lower demand following the end of the pandemic. In 2024, revenues from Paxlovid and Comirnaty continue ...

Fiera Capital Corp trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer (PFE) continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 ...

Pfizer shares climbed in early trading. The drugmaker said it made a one-time delivery of a million Paxlovid treatment courses to the U.S. Strategic National Stockpile in the third quarter. Pfizer ...